As filed with the Securities and Exchange
Commission on May 4, 2015
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM S-3
REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933
Amarantus Bioscience Holdings, Inc.
(Exact name of registrant
as specified in its charter)
Nevada |
26-0690857 |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
655 Montgomery Street, Suite 900
San Francisco, CA 94111
Telephone: (408) 737-2734
(Address, including
zip code, and telephone number, including area code, of registrant’s principal executive offices)
Gerald Commissiong, Chief Executive Officer
655 Montgomery Street, Suite 900
San Francisco, CA 94111
Telephone: (408) 737-2734
(Name, address including
zip code, and telephone number, including area code, of agent for service)
With copies to:
Jeffery Fessler, Esq.
Marcelle S. Balcombe, Esq.
Sichenzia Ross Friedman Ference LLP
61 Broadway, 32nd Floor
New York, New York 10006
Telephone: (212) 930-9700
Facsimile: (212) 930-9725
Approximate date of commencement of proposed
sale to the public: From time to time after the effective date of this registration statement.
If
the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please
check the following box.¨
If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under
the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check
the following box. x
If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check
the following box and list the Securities Act registration statement number of the earlier effective registration statement for
the same offering. ¨
If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
If
this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become
effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ¨
If
this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register
additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following
box. ¨
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
of “large accelerated filer”, “accelerated filer” and “smaller reporting company”
in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer ¨ |
|
Accelerated filer ¨ |
|
Non-accelerated filer ¨ |
|
Smaller reporting company x |
|
|
|
|
(Do not check if smaller reporting company) |
Title of Each Class of Securities to be Registered | |
Amount to be Registered(1) | | |
Proposed Maximum Offering Price Per Unit | | |
Proposed Maximum Aggregate Offering Price(2) | | |
Amount of Registration Fee(3) | |
Primary Offering | |
| | | |
| | | |
| | | |
| | |
Common Stock, $.001 par value per share | |
| — | | |
| — | | |
| — | | |
| — | |
Preferred Stock, $.001 par value per share | |
| — | | |
| — | | |
| — | | |
| — | |
Warrants | |
| — | | |
| — | | |
| — | | |
| — | |
Units(4) | |
| — | | |
| — | | |
| — | | |
| — | |
Total | |
| — | | |
| — | | |
$ | 150,000,000 | | |
$ | 17,430 | |
(1) |
There are being registered under this registration
statement such indeterminate number of shares of common stock and preferred stock; such indeterminate number of warrants to purchase
common stock, preferred stock, and/or units; and such indeterminate number of units as may be sold by the registrant from time
to time, which together shall have an aggregate initial offering price not to exceed $150,000,000. Any securities registered hereunder
may be sold separately or as units with other securities registered hereunder. The securities registered hereunder also include
such indeterminate number of shares of common stock and preferred stock, and warrants as may be issued upon conversion of or exchange
for preferred stock, upon exercise of warrants; or pursuant to the anti-dilution provisions of any such securities. In addition,
pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), the shares being registered
hereunder include such indeterminate number of shares of common stock and preferred stock as may be issuable with respect to the
shares being registered hereunder as a result of stock splits, stock dividends, or similar transactions. |
(2) |
Not required to be included in accordance with General Instruction II.D. of Form S-3 under the Securities Act. |
(3) |
Calculated pursuant to Rule 457(o) under the Securities Act based on the proposed maximum aggregate offering price of all securities listed. |
(4) |
Each unit will represent an interest in two or more other securities, which may or may not be separable from one another. |
The Registrant hereby amends this Registration Statement
on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment that
specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of
the Securities Act or until this Registration Statement shall become effective on such date as the Commission, acting pursuant
to said Section 8(a), may determine.
The information in this prospectus is not complete
and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission
is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these
securities in any jurisdiction where the offer or sale is not permitted.
PROSPECTUS |
SUBJECT TO COMPLETION, |
DATED MAY 4, 2015 |
$150,000,000
Common Stock
Preferred Stock
Warrants
Units |
|
|
We may offer and sell, from time to time in one or more offerings,
any combination of common stock, preferred stock, warrants or units having an aggregate initial offering price not exceeding $150,000,000.
The preferred stock, warrants, and units may be convertible or exercisable or exchangeable for common stock or preferred stock
or other securities of ours. When we decide to sell a particular class or series of securities, we will provide specific terms
of the offered securities in a prospectus supplement.
We will provide specific terms of the offerings of our securities
in supplements to this prospectus. The prospectus supplement may also add, update or change information in this prospectus. You
should read this prospectus and any prospectus supplement, as well as the documents incorporated by reference or deemed to be incorporated
by reference into this prospectus, carefully before you invest.
This prospectus may not be used to offer or sell our securities
unless accompanied by a prospectus supplement relating to the offered securities.
Our common stock is presently traded on the OTC QB under the
symbol “AMBS.” On May 1, 2015, the last reported sale price of our common stock was $0.0471.
These securities may be sold directly by us, through dealers
or agents designated from time to time, to or through underwriters, dealers or through a combination of these methods on a continuous
or delayed basis. See “Plan of Distribution” in this prospectus. We may also describe the plan of distribution
for any particular offering of our securities in a prospectus supplement. If any agents, underwriters or dealers are involved in
the sale of any securities in respect of which this prospectus is being delivered, we will disclose their names and the nature
of our arrangements with them in a prospectus supplement. The net proceeds we expect to receive from any such sale will also be
included in a prospectus supplement.
Investing in our securities involves various risks. See
“Risk Factors” beginning on page 6 for more information on these risks. Additional risks will be described
in the related prospectus supplements under the heading “Risk Factors”. You should review that section of the related
prospectus supplements for a discussion of matters that investors in our securities should consider.
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities, or passed upon the adequacy or accuracy of this prospectus
or any accompanying prospectus supplement. Any representation to the contrary is a criminal offense.
The date of this prospectus is ,
2015.
TABLE OF CONTENTS
ABOUT THIS PROSPECTUS
This prospectus is part of a shelf registration
statement that we filed with the Securities and Exchange Commission (the “SEC”) using a “shelf” registration
process. Under this shelf registration process, we may sell any combination of the securities described in this prospectus in one
or more offerings from time to time having an aggregate initial offering price of $150,000,000,. This prospectus provides you with
a general description of the securities we may offer. Each time we offer securities, we will provide you with a prospectus supplement
that describes the specific amounts, prices and terms of the securities we offer. The prospectus supplement also may add, update
or change information contained in this prospectus. You should read carefully both this prospectus and any prospectus supplement
together with additional information described below under the caption “Where You Can Find More Information.”
This prospectus does not contain all the
information provided in the registration statement we filed with the SEC. You should read both this prospectus, including the section
titled “Risk Factors,” and the accompanying prospectus supplement, together with the additional information described
under the heading “Where You Can Find More Information.”
You should rely only on the information
contained or incorporated by reference in this prospectus or a prospectus supplement. We have not authorized any other person to
provide you with different information. If anyone provides you with different or inconsistent information, you should not rely
on it. This prospectus is not an offer to sell securities, and it is not soliciting an offer to buy securities in any jurisdiction
where the offer or sale is not permitted. You should assume that the information appearing in this prospectus or any prospectus
supplement, as well as information we have previously filed with the SEC and incorporated by reference, is accurate as of the date
on the front of those documents only. Our business, financial condition, results of operations and prospects may have changed since
those dates.
OUR BUSINESS
Company Overview
Amarantus Bioscience Holdings, Inc. (the
“Company”) is a California based biopharmaceutical company founded in January 2008. We own or have exclusive licenses
to various product candidates in the biopharmaceutical and diagnostic areas of the healthcare industry. We are developing our
diagnostic product candidates in the field of neurology, and our therapeutic product candidates in the areas of neurology, psychiatry,
ophthalmology and regenerative medicine. Our business model is to develop our product candidates through various de-risking
milestones that we believe will be accretive to shareholder value, and will position them to be strategically partnered with pharmaceutical
companies, diagnostic companies and/or other stakeholders in order to more efficiently achieve regulatory approval and commercialization.
We have three operating divisions: the
diagnostics division; the therapeutics division; and the other drug discovery division.
Diagnostics Division
Within our diagnostics division, we are
developing the following product candidates:
LymPro Test ®
The Lymphocyte Proliferation Test
(“LymPro Test®”, or “LymPro”) is a diagnostic blood test for Alzheimer’s disease originally developed
by the University of Leipzig in Germany. The test works by evaluating the cell surface marker CD69 on peripheral blood lymphocytes
following a mitogenic stimulation. The underlying scientific basis for LymPro is that Alzheimer’s patients have a dysfunctional
cellular machinery division process that inappropriately allows mature neurons in the brain to enter the mitotic process (cell
division /cell cycle). When this happens the neurons start the cell division process, but cannot complete the process. As a result,
a number of cytokines and other genes are up-regulated, ultimately leading to cell death by apoptosis. This inappropriate cell
division activation process is also present in the lymphocytes of Alzheimer’s patients, as lymphocytes share similar cellular
division machinery with brain neurons. We measure the integrity of this cellular machinery division process by measuring CD69 up-regulation
in response to the mitogenic stimulation. If CD 69 is up-regulated it means that the cellular machinery division process is correct
and Alzheimer’s is not present. If CD69 is not up-regulated, it means there is a dysfunctional cellular machinery division
process, and Alzheimer’s is more likely. Data has been published in peer-reviewed publications on LymPro with 160 patients,
demonstrating 92% co-positivity and 91% co-negativity with an overall 95% accuracy rating for LymPro.
In 2014, we completed a 'Fit-for-Purpose'
assay validation for LymPro at Icon Central Laboratories in Farmingdale, NY, enabling LymPro to be offered to the pharmaceutical
industry for diagnosis of patients entering clinical trials for Alzheimer’s disease, as a means of mitigating the risk of
selecting the wrong patients for inclusion in such clinical studies. Biomarker services using LymPro Test® biomarker data are
now available to the pharmaceutical industry for Investigational Use Only (IUO), in such pharmaceutical therapeutic clinical development
programs.
MSPrecise®
In January 2015, we acquired MSPrecise®,
which is a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple
sclerosis (RRMS) at first clinical presentation. MSPrecise® utilizes next-generation sequencing to measure
DNA mutations found in rearranged immunoglobulin genes in immune cells initially isolated from cerebrospinal fluid. If successful,
MSPrecis® should augment the current standard of care for the diagnosis of MS, by providing a more accurate
assessment of a patient's immune response to a challenge within the central nervous system. MSPrecise® offers
a novel method of measuring changes in adaptive human immunity and may also be able to discern individuals whose disease is more
progressive and requires more aggressive treatment.
Final results from a pivotal clinical validation study demonstrated
that MSPrecise® met the primary study endpoint in patients suspected of having RRMS. MSPrecise® provided
a clear improvement in classifying early-stage RRMS patients when compared with the published performance for the current diagnostic
standard of care by cerebrospinal fluid (CSF) analysis. In this study, MSPrecise® not only performed well as
a standalone test but, when combined with the current standard of diagnosis, oligoclonal banding (OCB), it demonstrated that it
can substantially reduce the number of both false positives and false negatives as compared to use of OCB alone.
Additional Diagnostic Biomarkers
In January 2015, we entered into a one-year, option agreement
with Georgetown University for an exclusive license of patent rights related to certain blood based biomarkers for memory loss
that Georgetown University and University of Rochester jointly developed and own (the “Georgetown Biomarkers”). In
the event that we exercise this option, conditions and milestones will be defined; such as, providing Georgetown with development
and commercialization plans for the biomarkers and recruiting a senior executive to lead our diagnostics division, as well as other
requirements defined in the option agreement. The diagnostic technologies subject to this option agreement are based on metabolic,
genetic and exosomal biomarkers. We believe these may hold additional potential for identifying distinguishing factors in dementia
and Alzheimer's disease that will be complementary to our LymPro Test® diagnostic for Alzheimer’s
disease. With the potential addition of the Georgetown Biomarkers to our Alzheimer's diagnostics portfolio, we
are positioning ourselves to provide all three modalities (cell cycle dysregulation, lipidomics and exosomes) for diagnosis
of Alzheimer’s disease.
In May 2013, we acquired the intellectual
property rights to two diagnostic blood test platforms known as NuroPro and BC-SeraPro from the bankruptcy estate of Power3 Medical
Products. NuroPro is a neurodegenerative disease diagnostic platform with a lead application in Parkinson’s disease. BC-SeraPro
is an oncology diagnostic platform with a lead application in breast cancer. Further development of our NuroPro and BC-SeraPro
diagnostic platforms are on hold, as we apply our resources to the continuing development of our LymPro Test® and
MSPrecise diagnostics, as well as our planned development of the Georgetown Biomarkers.
Therapeutics Division
Within the therapeutics division, we are
developing the following product candidates:
Eltoprazine
Eltoprazine is a small molecule 5HT1a/1b
partial agonist in clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD LID) and Adult
Attention Deficit Hyperactivity Disorder (“Adult ADHD”). Eltoprazine has been evaluated in over 600 human subjects
to date, with a very strong and well-established safety profile. Eltoprazine was originally developed by Solvay Pharmaceuticals
for the treatment of aggression. Solvay out-licensed the Eltoprazine program to PsychoGenics. PsychoGenics licensed Eltoprazine
to Amarantus following successful Phase 2a studies in both PD-LID and Adult ADHD, in which both primary and secondary endpoints
were met.
In February 2015, we submitted an Investigational New Drug Application
(“ IND”) to the FDA for the Phase 2b program clinical trial for Eltoprazine in PD LID, and in March 2015, we received
notification of approval from the FDA that the IND was approved. We are now in the process of initiating this Phase 2b clinical
study. Following the initiation of the clinical study of Eltoprazine in PD LID, we intend to submit a request to the FDA regarding
further clinical development of Eltoprazine in Adult ADHD.
MANF
MANF (mesencephalic-astrocyte-derived neurotrophic factor) is
believed to have broad potential because it is a naturally-occurring protein produced by the body for the purpose of reducing and
preventing apoptosis (cell death) in response to injury or disease, via the unfolded protein response. MANF was discovered by the
Company’s Chief Scientific Officer, Dr. John Commissiong. By manufacturing MANF and administering it to the body, Amarantus
is seeking to use a regenerative medicine approach to assist the body with higher quantities of MANF when needed. Amarantus is
the front-runner and primary holder of intellectual property around MANF, and is focusing on the development of MANF-based protein
therapeutics. MANF has demonstrated efficacy as a disease-modifying treatment in various animal models, including retinitis pigmentosa,
Parkinson’s disease, cardiac ischemia and stroke.
We made a strategic decision to focus the development of MANF
in orphan indications. The FDA Orphan Drug Designation program provides a special status to drugs and biologics intended to treat,
diagnose or prevent so-called orphan diseases and disorders that affect fewer than 200,000 people in the U.S. This designation
provides for a seven-year marketing exclusivity period against competition, as well as certain incentives, including federal grants,
tax credits and a waiver of PDUFA filing fees.
In December 2014, the FDA granted MANF orphan drug designation
for the treatment of retinitis pigmentosa (RP) and in April 2015 the European Medicines Agency Committee for Orphan Medicinal Products
also granted orphan drug status for MANF for the treatment of RP. RP refers to a group of inherited diseases causing retinal degeneration
often leading to blindness. Pre-clinical data showed that MANF provided protective functional effects in an animal model of RP.
Moreover, toxicology studies have demonstrated that MANF was well tolerated following a single intravitreal administration of a
therapeutically relevant dose. Our goal is to continue to build value in our MANF program by seeking other orphan drug designations
for MANF, and by continuing work to advance this promising product candidate toward clinical testing in multiple therapeutic areas.
Option to Acquire Additional Product
Candidate - Engineered Skin Substitute
In November 2014, we entered into an exclusive option agreement
to acquire Engineered Skin Substitute (ESS), an autologous skin replacement product for the treatment of Stage 3 and Stage 4 intractable
severe burns. As part of the option agreement, we have also agreed to engage Lonza Walkersville, Inc., a subsidiary of Lonza Group
Ltd., to produce ESS for human clinical trials and subsequent commercial distribution.
ESS is a tissue-engineered skin prepared from autologous (patient's
own) skin cells. It is a combination of cultured epithelium with a collagen-fibroblast implant that produces a skin substitute
that contains both epidermal and dermal components. This model has been shown in preclinical studies to generate a functional skin
barrier. Most importantly, the researchers consider self-to-self skin grafts for autologous skin tissue to be ideal because they
are less likely to be rejected by the immune system of the patient, unlike with porcine or cadaver grafts in which immune system
rejection is an important possibility.
ESS has the potential to become a revolutionary new treatment
for severe burns. The product is produced from a small sample of the patient's own healthy skin. The sample is harvested from a
portion of healthy skin remaining on a burn patient's body and is then shipped to Lonza’s central laboratory facility for
expansion. The proprietary ESS technology can then be applied to produce an expanded sample or graft that is sufficiently large
enough to close severe wounds covering the majority of an individual's body, including both the epidermal and dermal layers of
the skin. The expanded skin samples are then shipped back in rectangular shapes, with the dimensions of approximately 10 inches
by 10 inches, to the severe burn center for surgical transplantation onto the original patient to facilitate wound closure. Wound
closure is of critical importance in this setting to promote healing and to reduce the risk of a variety of infections, including
sepsis.
ESS is being developed with support from
a grant from the Armed Forces Institute for Regenerative Medicine (AFIRM). The AFIRM grant was awarded to support the IND
and initial clinical studies. Upon execution of our option to acquire ESS, we anticipate initiating a 10 patient Phase 2 clinical
study to evaluate the efficacy of ESS versus meshed split thickness autograft, the current standard of care for the treatment of
Stage 3 and Stage 4 intractable severe burns.
Drug Discovery Division
MANF was discovered utilizing our proprietary PhenoGuard™
protein discovery technology, and we believe that this drug discovery platform can be used to discover other, similar neurrotrophic
factors. Our PhenoGuard™ technology currently consists of 88 cell lines, and we intend to expand the number of such cell
lines as we conduct research directed towards the discovery of such additional neurotrophic factors.
Corporate Information
We were incorporated on January 14, 2008 in the state of
Delaware and were reincorporated in Nevada on March 22, 2013. The Company is a development stage biopharmaceutical drug development
holding company dedicated to sourcing high-potential therapeutic and diagnostic platform technologies and aligning their development
with complementary biopharmaceutical assets to reduce overall enterprise risk. Our principal executive offices are located at 655
Montgomery Street, Suite 900, San Francisco, CA 94111 and our telephone number is (415) 688-4484. Our website address
is http:// http://www.amarantus.com/. The information on, or that can be accessed through, our website is not part of this prospectus.
RISK FACTORS
You should carefully consider the risks
described below before making an investment decision. The risks described below are not the only ones we face. Additional risks
we are not presently aware of or that we currently believe are immaterial may also impair our business operations. Our business
could be harmed by any of these risks. The trading price of our common stock could decline due to any of these risks, and you may
lose all or part of your investment. In assessing these risks, you should also refer to the other information contained or incorporated
by reference into this prospectus supplement and the accompanying prospectus, including our financial statements and related notes.
Risks Related to Our Product Candidates
and Operations
We are largely dependent on the success
of our lead product candidates, LymPro, Eltoprazine and MANF, and we may not be able to successfully commercialize these products.
We have incurred and
will continue to incur significant costs relating to the development of our lead product candidates, LymPro, Eltoprazine and MANF.
We have not obtained approval to commercialize LymPro, Eltoprazine and MANF in any jurisdiction and we may never be able to obtain
approval or, if approvals are obtained, to commercialize LymPro, Eltoprazine and MANF successfully.
If we fail to successfully
commercialize our products, we may be unable to generate sufficient revenue to sustain and grow our business, and our business,
financial condition and results of operations will be adversely affected.
If we fail to obtain U.S. regulatory
approval of LymPro, Eltoprazine, MANF or any of our other current or future product candidates, we will be unable to commercialize
these potential products in the United States.
The development, testing,
manufacturing and marketing of our product candidates are subject to extensive regulation by governmental authorities in the United
States. In particular, the process of obtaining FDA approval is costly and time consuming, and the time required for such approval
is uncertain. Our product candidates must undergo rigorous preclinical and clinical testing and an extensive regulatory approval
process mandated by the FDA. Such regulatory review includes the determination of manufacturing capability and product performance.
Generally, only a small percentage of pharmaceutical products are ultimately approved for commercial sale.
We can give no assurance
that our current or future product candidates will be approved by the FDA or any other governmental body. In addition, there can
be no assurance that all necessary approvals will be granted for future product candidates or that FDA review or actions will not
involve delays caused by requests for additional information or testing that could adversely affect the time to market for and
sale of our product candidates. Further failure to comply with applicable regulatory requirements can, among other things, result
in the suspension of regulatory approval as well as possible civil and criminal sanctions.
Our proprietary rights may not adequately
protect our intellectual property and product candidates and if we cannot obtain adequate protection of our intellectual property
and product candidates, we may not be able to successfully market our product candidates.
Our commercial success
will depend in part on obtaining and maintaining intellectual property protection for our technologies and product candidates.
We will only be able to protect our technologies and product candidates from unauthorized use by third parties to the extent that
valid and enforceable patents cover them, or those other market exclusionary rights apply.
While we have issued
enforceable patents covering our product candidates, the patent positions of life sciences companies, like ours, can be highly
uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent
policy regarding the breadth of claims allowed in such companies' patents has emerged to date in the United States. The general
patent environment outside the United States also involves significant uncertainty. Accordingly, we cannot predict the breadth
of claims that may be allowed or that the scope of these patent rights would provide a sufficient degree of future protection that
would permit us to gain or keep our competitive advantage with respect to these products and technology.
Our issued patents
may be subject to challenge and possibly invalidated by third parties. Changes in either the patent laws or in the interpretations
of patent laws in the United States or other countries may diminish the market exclusionary ability of our intellectual property.
In addition, others
may independently develop similar or alternative compounds and technologies that may be outside the scope of our intellectual property.
Should third parties obtain patent rights to similar compounds or radiolabeling technology, this may have an adverse effect on
our business.
To the extent that
consultants or key employees apply technological information independently developed by them or by others to our product candidates,
disputes may arise as to the proprietary rights of the information, which may not be resolved in our favor. Consultants and key
employees that work with our confidential and proprietary technologies are required to assign all intellectual property rights
in their discoveries to us. However, these consultants or key employees may terminate their relationship with us, and we cannot
preclude them indefinitely from dealing with our competitors. If our trade secrets become known to competitors with greater experience
and financial resources, the competitors may copy or use our trade secrets and other proprietary information in the advancement
of their products, methods or technologies. If we were to prosecute a claim that a third party had illegally obtained and was
using our trade secrets, it would be expensive and time consuming and the outcome would be unpredictable. In addition, courts
outside the United States are sometimes less willing to protect trade secrets than courts in the United States. Moreover, if our
competitors independently develop equivalent knowledge, we would lack any contractual claim to this information, and our business
could be harmed.
If our product candidates, including
LymPro, Eltoprazine, MANF, do not gain market acceptance among physicians, patients and the medical community, we will be unable
to generate significant revenue, if any.
The products that we
develop may not achieve market acceptance among physicians, patients, third-party payers and others in the medical community. If
we, or any of our partners, receive the regulatory approvals necessary for commercialization, the degree of market acceptance will
depend upon a number of factors, including:
|
- |
limited indications of regulatory approvals; |
|
- |
the establishment and demonstration in the medical community of the clinical efficacy and safety of our product candidates and their potential advantages over existing diagnostic compounds; |
|
- |
the prevalence and severity of any side effects; |
|
- |
our ability to offer our product candidates at an acceptable price; |
|
- |
the relative convenience and ease of administration of our products; |
|
- |
the strength of marketing and distribution support; and |
|
- |
sufficient third-party coverage or reimbursement. |
The market may not accept LymPro, Eltoprazine
or MANF based products based on any number of the above factors. The market may choose to continue utilizing the existing products
for any number of reasons, including familiarity with or pricing of these existing products. The failure of any of our product
candidates to gain market acceptance could impair our ability to generate revenue, which could have a material adverse effect on
our future business and prevent us from obtaining the necessary partnerships to further our business strategy.
Risks Associated with Our Financial Condition
Our independent registered public accounting firm has
expressed substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing.
Our consolidated financial statements as
of December 31, 2014 were prepared under the assumption that we will continue as a going concern for the next twelve months.
Our independent registered public accounting firm has issued a report that included an explanatory paragraph referring to our projected
future losses along with recurring losses from operations and expressing substantial doubt in our ability to continue as a going
concern without additional capital becoming available. Our ability to continue as a going concern is dependent upon our ability
to obtain additional equity or debt financing, attain further operating efficiencies, reduce expenditures, and, ultimately, to
generate revenue. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
We are at an early stage of development as a company and
currently have no source of revenue and may never become profitable.
We are a development stage biopharmaceutical
company. Currently, we have no products approved for commercial sale and, to date, we have not generated any revenue. Our ability
to generate revenue depends heavily on:
|
- |
demonstration in future clinical trials that our product candidate, MANF for the treatment of PD is safe and effective; |
|
- |
our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; |
|
- |
successful manufacture and commercialization of our product candidates; and |
|
- |
market acceptance of our products. |
All of our existing product candidates are
in various stages of development and will require extensive additional preclinical and clinical evaluation, regulatory review and
approval, significant marketing efforts and substantial investment before they could provide us with any revenue. As a result,
if we do not successfully develop, achieve regulatory approval and commercialize LymPro, Eltoprazine and/or MANF, we will be unable
to generate any revenue for many years, if at all. We do not anticipate that we will generate revenue for several years, at the
earliest, or that we will achieve profitability for at least several years after generating material revenue, if at all. If we
are unable to generate revenue, we will not become profitable, and we may be unable to continue our operations.
We do not have any products that are approved for commercial
sale and therefore do not expect to generate any revenues from product sales in the foreseeable future, if ever.
We currently do not have any products that
are approved for commercial sale. To date, we have funded our operations primarily from grants and sales of our securities. We
have not received, and do not expect to receive for at least the next several years in the case of Eltoprazine and MANF and
until the first half of 2015 in the case of LymPro, if at all, any revenues from the commercialization of our product candidates.
To obtain revenues from sales of our product candidates, we must succeed, either alone or with third parties, in developing, obtaining
regulatory approval for, manufacturing and marketing drugs with commercial potential. We may never succeed in these activities,
and may not generate sufficient revenues to continue our business operations or achieve profitability.
We have incurred significant losses since inception and
anticipate that we will incur continued losses for the foreseeable future.
As of December 31, 2014 we had an accumulated
deficit of approximately $55 million. We have incurred significant losses since inception. We expect to incur significant and increasing
operating losses for the next several years as we expand our research and development, advance product candidates into clinical
development, complete clinical trials, seek regulatory approval and, if we receive FDA approval, commercialize our products. Because
of the numerous risks and uncertainties associated with product development efforts, we are unable to predict the extent of any
future losses or when we will become profitable, if at all. If we are unable to achieve and then maintain profitability, the market
value of our common stock will likely decline.
We will need to raise substantial additional capital to
fund our operations, and our failure to obtain funding when needed, may force us to delay, reduce or eliminate certain product
development programs.
We expect to continue to spend substantial
amounts to:
|
- |
continue development of our product candidates; |
|
- |
finance our general and administrative expenses; |
|
- |
license or acquire additional technologies; |
|
- |
manufacture product for clinical trials; |
|
- |
launch and commercialize our product candidates, if any such product candidates receive regulatory approval; and |
|
- |
develop and implement commercial manufacturing, sales, marketing and distribution capabilities. |
We will be required to raise additional
capital to complete the development and commercialization of our product candidates and to continue to fund operations at the current
cash expenditure levels. Our future funding requirements will depend on many factors, including, but not limited to:
|
- |
the rate of progress and cost of our clinical trials and other development activities; |
|
- |
any future decisions we may make about the scope and prioritization of the programs we pursue; |
|
- |
the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; |
|
- |
the costs of manufacturing product; |
|
- |
the costs and timing of regulatory approval; |
|
- |
the costs of establishing sales, marketing and distribution capabilities; |
|
- |
the effect of competing technological and market developments; |
|
- |
the terms and timing of any collaborative, licensing and other arrangements that we may establish; and |
|
- |
general market conditions for offerings from biopharmaceutical companies. |
Worldwide economic conditions and the international
equity and credit markets have recently significantly deteriorated and may remain depressed for the foreseeable future. These developments
could make it more difficult for us to obtain additional equity or credit financing, when needed.
We cannot be certain that funding will be
available on acceptable terms, or at all. To the extent that we raise additional funds by issuing equity securities, our stockholders
may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact our ability
to conduct our business. If we are unable to raise additional capital when required or on acceptable terms, we may have to significantly
delay, scale back or discontinue the development and/or commercialization of one or more of our product candidates. We also may
be required to:
|
- |
seek collaborators for our product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; and/or |
|
- |
relinquish license or otherwise dispose of rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize ourselves on unfavorable terms. if we are unable to fund our operations, we may be forced to discontinue and wind down our business. |
We may require additional financing to sustain our operations
and without it we may not be able to continue operations.
At December 31, 2014, we had a working capital
deficit of $5,900,000. We have never had positive operating cash flow. For the year ended December 31, 2014, we incurred an operating
cash flow deficit of $11,331,000. We do not currently have sufficient financial resources to fund our operations or those of our
subsidiaries. Therefore, we need additional funds to continue these operations.
We may direct Lincoln Park to purchase
up to an additional $17,326,000 worth of shares of our common stock under our agreement generally in amounts up to 1,000,000
shares of our common stock on any such business day, which amounts may be increased to up to 2,500,000, provided the closing
price of our common stock exceeds a certain threshold with a maximum limit of up to $500,000 worth of our common stock on any
single business day, plus an additional “accelerated amount” under certain circumstances. However, Lincoln Park
shall not purchase any shares of our common stock on any business day that the closing sale price of our common stock is less
than $0.04 per share, subject to adjustment as set forth in the Purchase Agreement. Assuming a purchase price of $0.0822 per
share (the closing sale price of the common stock on December 31, 2014) and the purchase by Lincoln Park of the full
76,500,000 purchase shares under the purchase agreement, proceeds to us would only be $6,288,300. As of May 1, 2015, the
Company had received $5,493,881 from Lincoln Park in consideration for the issuance of an aggregate of 64,486,921 Company
common shares, of which 961,437 shares were for commitment fees.
The extent we rely on Lincoln Park as a
source of funding will depend on a number of factors including, the prevailing market price of our common stock and the extent
to which we are able to secure working capital from other sources. If obtaining sufficient funding from Lincoln Park were to prove
unavailable or prohibitively dilutive, we will need to secure another source of funding in order to satisfy our working capital
needs. Even if we sell all $20,000,000 under the Purchase Agreement to Lincoln Park, we will need additional capital to fully implement
our business, operating and development plans. Should the financing we require to sustain our working capital needs be unavailable
or prohibitively expensive when we require it, the consequences could be a material adverse effect on our business, operating results,
financial condition and prospects.
Risks Associated with Management
If we are unable to hire and retain key personnel,
we may not be able to implement our business plan.
Due to the specified nature of our business,
having certain key personnel is essential to the development and marketing of the products we plan to sell and thus to the entire
business itself. Consequently, the loss of any of those individuals may have a substantial effect on our future success or failure.
We may have to recruit qualified personnel with competitive compensation packages, equity participation, and other benefits that
may affect the working capital available for our operations. Management may have to seek to obtain outside independent professionals
to assist them in assessing the merits and risks of any business proposals as well as assisting in the development and operation
of many company projects. No assurance can be given that we will be able to obtain such needed assistance on terms acceptable to
us. Our failure to attract additional qualified employees or to retain the services of key personnel could have a material adverse
effect on our operating results and financial condition.
Risks Related to Our Common Stock
Our stock price may be volatile.
The stock market, particularly
in recent years, has experienced significant volatility particularly with respect to pharmaceutical, biotechnology and other life
sciences company stocks. The volatility of pharmaceutical, biotechnology and other life sciences company stocks often does not
relate to the operating performance of the companies represented by the stock. Factors that could cause this volatility in the
market price of our common stock include:
|
- |
results from and any delays in our clinical trials; |
|
- |
failure or delays in entering additional product candidates into clinical trials; |
|
- |
failure or discontinuation of any of our research programs; |
|
- |
research publications that are unfavorable; |
|
- |
delays in establishing new strategic relationships; |
|
- |
delays in the development or commercialization of our potential products; |
|
- |
market conditions in the pharmaceutical and biotechnology sectors and issuance of new or changed securities analysts' reports or recommendations; |
|
- |
actual and anticipated fluctuations in our financial and operating results; |
|
- |
developments or disputes concerning our intellectual property or other proprietary rights; |
|
- |
introduction of technological innovations or new commercial products by us or our competitors; |
|
- |
issues in manufacturing our potential products; |
|
- |
market acceptance of our potential products; |
|
- |
third-party healthcare reimbursement policies; |
|
- |
FDA or other domestic or foreign regulatory actions affecting us or our industry; |
|
- |
litigation or public concern about the safety of our product candidates; and |
|
- |
additions or departures of key personnel. |
These and other external
factors may cause the market price and demand for our common stock to fluctuate substantially, which may limit or prevent investors
from readily selling their shares of common stock and may otherwise negatively affect the liquidity of our common stock. In the
past, when the market price of a stock has been volatile, holders of that stock have instituted securities class action litigation
against the company that issued the stock. If any of our stockholders brought a lawsuit against us, we could incur substantial
costs defending the lawsuit. Such a lawsuit could also divert the time and attention of our management.
We have not and do not anticipate
paying any dividends on our common stock.
We have paid no dividends
on our common stock to date and it is not anticipated that any dividends will be paid to holders of our common stock in the foreseeable
future. While our future dividend policy will be based on the operating results and capital needs of the business, it is currently
anticipated that any earnings will be retained to finance our future expansion and for the implementation of our business plan.
As an investor, you should take note of the fact that a lack of a dividend can further affect the market value of our stock, and
could significantly affect the value of any investment in our Company.
If we fail to establish and
maintain an effective system of internal control, we may not be able to report our financial results accurately or to prevent
fraud. Any inability to report and file our financial results accurately and timely could harm our reputation and adversely
impact the trading price of our common stock.
Effective internal
control is necessary for us to provide reliable financial reports and prevent fraud. We have not performed an in-depth
analysis to determine if historical un-discovered failures of internal controls exist, and may in the future discover areas of
our internal control that need improvement. If we cannot provide reliable financial reports or prevent fraud, we may not be able
to manage our business as effectively as we would if an effective control environment existed, and our business and reputation
with investors may be harmed. As a result, our small size and any current internal control deficiencies may adversely
affect our financial condition, results of operation and access to capital.
Our common stock is currently deemed
a “penny stock,” which makes it more difficult for our investors to sell their shares.
Our common stock is subject to the “penny
stock” rules adopted under Section 15(g) of the Exchange Act. The penny stock rules generally apply to companies
whose common stock is not listed on The Nasdaq Stock Market or other national securities exchange and trades at less than $5.00
per share, other than companies that have had average revenue of at least $6,000,000 for the last three years or that have tangible
net worth of at least $5,000,000 ($2,000,000 if the company has been operating for three or more years). These rules
require, among other things, that brokers who trade penny stock to persons other than “established customers” complete
certain documentation, make suitability inquiries of investors and provide investors with certain information concerning trading
in the security, including a risk disclosure document and quote information under certain circumstances. Many brokers
have decided not to trade penny stocks because of the requirements of the penny stock rules and, as a result, the number of broker-dealers
willing to act as market makers in such securities is limited. If we remain subject to the penny stock rules for any
significant period, it could have an adverse effect on the market, if any, for our securities. If our securities are
subject to the penny stock rules, investors will find it more difficult to dispose of our securities.
Offers or availability for sale of a substantial number
of shares of our common stock may cause the price of our common stock to decline.
If our stockholders sell substantial amounts
of our common stock in the public market upon the expiration of any statutory holding period, under Rule 144, or issued upon the
exercise of outstanding options or warrants, it could create a circumstance commonly referred to as an “overhang” and
in anticipation of which the market price of our common stock could fall. The existence of an overhang, whether or not
sales have occurred or are occurring, also could make more difficult our ability to raise additional financing through the sale
of equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate.
Our certificate of incorporation allows for our board
to create new series of preferred stock without further approval by our stockholders, which could adversely affect the rights of
the holders of our common stock.
Our board of directors has the authority
to fix and determine the relative rights and preferences of preferred stock and has designated 250,000 preferred shares as Series
A Convertible Preferred Stock, 3,000,000 as Series B Convertible Preferred Stock, 750,000 as Series C Convertible Preferred Stock,
1,300 as Series D 8% Convertible Preferred Stock, 13,335 as Series E 12% Convertible Preferred Stock and 10,000 as Series G Preferred
Stock. Our board of directors also has the authority to issue additional shares of our preferred stock without further stockholder
approval. As a result, our board of directors could authorize the issuance of a series of preferred stock that would grant to holders
the preferred right to our assets upon liquidation, the right to receive dividend payments before dividends are distributed to
the holders of common stock and the right to the redemption of the shares, together with a premium, prior to the redemption of
our common stock. In addition, our board of directors could authorize the issuance of a series of preferred stock that has greater
voting power than our common stock or that is convertible into our common stock, which could decrease the relative voting power
of our common stock or result in dilution to our existing stockholders.
Future sales or issuances of our securities may dilute
the ownership of existing stockholders and cause the market price of our common stock to decline.
Pursuant to a stock purchase
agreement, we have issued and sold to Discover Growth Fund, or the selling stockholder, 1,087 shares of Series G Preferred
Stock. Such shares of Series G Preferred Stock are convertible into a total of 90,583,333 shares of our common
stock, and upon the conversion of such shares, we also will be required to issue to the selling stockholder shares of common
stock as a Conversion Premium and pay the selling stockholder, dividends, at our sole and absolute discretion, either in cash
or in shares of our common stock. The number of shares of our common stock that may be issued pursuant to the
Conversion Premium and if we elect to pay such dividends in shares may be significant, but cannot be determined at this time
because the applicable calculations are based on our stock price during a period surrounding the date of
the conversion. Any such issuances of our common stock as a result of the conversion of Series G Preferred Stock
will dilute the proportionate ownership and voting power of existing stockholders and may cause the market price for our
common stock to decline.
The sale or issuance of our common stock to Lincoln Park
may cause dilution and the sale of the shares of common stock acquired by Lincoln Park, or the perception that such sales may occur,
could cause the price of our common stock to fall
On March 7, 2014, we entered into the Purchase
Agreement with Lincoln Park, pursuant to which Lincoln Park has committed to purchase up to $20,000,000 of our common stock. Concurrently
with the execution of the Purchase Agreement on March 7, 2014, we issued 4,000,000 shares of our common stock to Lincoln Park for
a total purchase price of $400,000 in the Initial Purchase under the Purchase Agreement and 6,000,000 Initial Commitment Shares
to Lincoln Park as a fee for its commitment to purchase additional shares of our common stock under the Purchase Agreement. The
additional shares that may be sold pursuant to the Purchase Agreement may be sold by us to Lincoln Park at our discretion from
time to time over a 30-month period commencing June 17, 2014.
Other than with respect to the Initial Purchase
by Lincoln Park under the Purchase Agreement, the purchase price for the shares that we may sell to Lincoln Park under the Purchase
Agreement will fluctuate based on the market price of our common stock. Depending on market liquidity at the time, sales of such
shares may cause the market price of our common stock to fall.
We generally have the right to
control the timing and amount of any sales of our shares to Lincoln Park, except that, pursuant to the terms of our agreements
with Lincoln Park, we would be unable to sell shares to Lincoln Park if and when the closing sale price of our common stock is
below $0.04 per share, subject to adjustment as set forth in the Purchase Agreement. Additional sales of our common stock, if any,
to Lincoln Park will depend upon market conditions and other factors to be determined by us. As such, other than the Initial Purchase,
Lincoln Park may ultimately purchase all, some or none of the shares of our common stock that may be sold pursuant to the Purchase
Agreement and, after it has acquired shares, Lincoln Park may sell all, some or none of those shares. Therefore, sales to Lincoln
Park by us could result in substantial dilution to the interests of other holders of our common stock. Additionally, the sale of
a substantial number of shares of our common stock to Lincoln Park, or the anticipation of such sales, could make it more difficult
for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect
sales.
DISCLOSURE REGARDING FORWARD-LOOKING
STATEMENTS
This prospectus and any accompanying prospectus
supplement, including the documents that we incorporate by reference, contains forward-looking statements. Such forward-looking
statements include those that express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise
are not statements of historical fact. These forward-looking statements are based on our current expectations and projections about
future events and they are subject to risks and uncertainties known and unknown that could cause actual results and developments
to differ materially from those expressed or implied in such statements.
In some cases, you can identify forward-looking
statements by terminology, such as “expects,” “anticipates,” “intends,” “estimates,”
“plans,” “believes,” “seeks,” “may,” “should”, “could”
or the negative of such terms or other similar expressions. Accordingly, these statements involve estimates, assumptions and
uncertainties that could cause actual results to differ materially from those expressed in them. Any forward-looking statements
are qualified in their entirety by reference to the factors discussed throughout this prospectus.
You should read this prospectus and any
accompanying prospectus supplement and the documents that we reference herein and therein and have filed as exhibits to the registration
statement, of which this prospectus is part, completely and with the understanding that our actual future results may be materially
different from what we expect. You should assume that the information appearing in this prospectus and any accompanying prospectus
supplement is accurate as of the date on the front cover of this prospectus or such prospectus supplement only. Because the
risk factors referred to above, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made
by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking
statement speaks only as of the date on which it is made, and we undertake no obligation to update any forward-looking statement
to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated
events. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition,
we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause
actual results to differ materially from those contained in any forward-looking statements. We qualify all of the information
presented in this prospectus and any accompanying prospectus supplement, and particularly our forward-looking statements, by these
cautionary statements.
USE OF PROCEEDS
Except as otherwise provided in the applicable
prospectus supplement, we intend to use the net proceeds from the sale of the securities offered by this prospectus for general
corporate purposes, which may include working capital, capital expenditures, research and development expenditures, regulatory
affairs expenditures, acquisitions of new technologies and investments, and the repayment, refinancing, redemption or repurchase
of future indebtedness or capital stock.
The intended application of proceeds from
the sale of any particular offering of securities using this prospectus will be described in the accompanying prospectus supplement
relating to such offering. The precise amount and timing of the application of these proceeds will depend on our funding requirements
and the availability and costs of other funds.
THE SECURITIES WE MAY OFFER
The descriptions of the securities contained
in this prospectus, together with the applicable prospectus supplements, summarize all the material terms and provisions of the
various types of securities that we may offer. We will describe in the applicable prospectus supplement relating to any securities
the particular terms of the securities offered by that prospectus supplement. If we indicate in the applicable prospectus supplement,
the terms of the securities may differ from the terms we have summarized below. We will also include in the prospectus supplement
information, where applicable, about material United States federal income tax considerations relating to the securities, and the
securities exchange, if any, on which the securities will be listed.
We may sell from time to time, in one or
more offerings:
|
• |
|
shares of our common stock; |
|
• |
|
shares of our preferred stock; |
|
• |
|
warrants to purchase any of the securities listed above; and/or |
|
• |
|
units consisting of any of the securities listed above. |
The terms of any securities we offer will
be determined at the time of sale. We may issue securities that are exchangeable for or convertible into common stock or any of
the other securities that may be sold under this prospectus. When particular securities are offered, a supplement to this prospectus
will be filed with the SEC, which will describe the terms of the offering and sale of the offered securities.
DESCRIPTION OF CAPITAL STOCK
General
The following description of common stock
and preferred stock, together with the additional information we include in any applicable prospectus supplements, summarizes the
material terms and provisions of the common stock and preferred stock that we may offer under this prospectus but is not complete.
For the complete terms of our common stock and preferred stock, please refer to our articles of incorporation, as amended, which
may be further amended from time to time, any certificates of designation for our preferred stock, and our amended and restated
bylaws, as amended from time to time. The Nevada Revised Statutes may also affect the terms of these securities. While the terms
we have summarized below will apply generally to any future common stock or preferred stock that we may offer, we will describe
the particular terms of any series of these securities in more detail in the applicable prospectus supplement. If we so indicate
in a prospectus supplement, the terms of any common stock or preferred stock we offer under that prospectus supplement may differ
from the terms we describe below.
As of May 1, 2015, our authorized
capital stock consisted of 2,000,000,000 shares of common stock, $0.001 par value per share, and 10,000,000 shares
of preferred stock, $0.001 par value per share, of which 250,000 are designated Series A Convertible Preferred Stock,
3,000,000 are designated Series B Convertible Preferred Stock, 750,000 are designated Series C Convertible Preferred Stock,
1,300 are designated Series D Convertible Preferred Stock, 13,335 are designated Series E Convertible Preferred Stock and
10,000 are designated Series G Preferred Stock. Our board of directors may establish the rights and preferences of the
preferred stock from time to time. As of May 1, 2015, there are 1,049,280,268 shares of our common stock issued and
outstanding and 750,000 shares of Series C Convertible Preferred Stock, 550 shares of Series D Convertible Preferred
Stock, 7,722.9 shares of Series E Convertible Preferred Stock and 1,087 shares of Series G Preferred Stock issued and
outstanding.
Common Stock
Holders of our common stock are entitled
to one vote per share. Our Certificate of Incorporation does not provide for cumulative voting. Holders of our common stock are
entitled to receive ratably such dividends, if any, as may be declared by our board of directors (the “Board”) out
of legally available funds. However, the current policy of our Board is to retain earnings if any, for the operation and expansion
of the Company. Upon liquidation, dissolution or winding-up, the holders of our common stock are entitled to share ratably in all
of our assets which are legally available for distribution, after payment of or provision for all liabilities. The holders of our
common stock have no preemptive, subscription, redemption or conversion rights.
Preferred Stock
Our Certificate of Incorporation provides
that our Board may by resolution, without further vote or action by the stockholders, establish one or more classes or series of
preferred stock having the number of shares and relative voting rights, designation, dividend rates, liquidation, and other rights,
preferences, and limitations as may be fixed by them without further stockholder approval. Once designated by our Board, each series
of preferred stock will have specific financial and other terms that will be described in a prospectus supplement. The description
of the preferred stock that is set forth in any prospectus supplement is not complete without reference to the documents that govern
the preferred stock. These include our Certificate of Incorporation and any certificates of designation that the Board may adopt. Prior
to the issuance of shares of each series of preferred stock, the Board is required by the Nevada Revised Statutes and the Certificate
of Incorporation to adopt resolutions and file a certificate of designation with the Secretary of State of the State of Nevada.
The certificate of designation fixes for each class or series the designations, powers, preferences, rights, qualifications, limitations
and restrictions, including, but not limited to, some or all of the following:
|
(a) |
The distinctive designation of such series and the number of shares which shall constitute such series, which number may be increased (except where otherwise provided by the Board in creating such series) or decreased (but not below the number of shares thereof then outstanding) from time to time by resolution of the Board; |
|
(b) |
The rate and manner of payment of dividends payable on shares of such series, including the dividend rate, date of declaration and payment, whether dividends shall be cumulative, and the conditions upon which and the date from which such dividends shall be cumulative; |
|
(c) |
Whether shares of such series shall be redeemed, the time or times when, and the price or prices at which, shares of such series shall be redeemable, the redemption price, the terms and conditions of redemption, and the sinking fund provisions, if any, for the purchase or redemption of such shares; |
|
(d) |
The amount payable on shares of such series and the rights of holders of such shares in the event of any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company; |
|
(e) |
The rights, if any, of the holders of shares of such series to convert such shares into, or exchange such shares for, shares of common stock, other securities, or shares of any other class or series of preferred stock and the terms and conditions of such conversion or exchange; |
|
(f) |
The voting rights, if any, and whether full or limited, of the shares of such series, which may include no voting rights, one vote per share, or such higher number of votes per share as may be designated by the Board; and |
|
(g) |
The preemptive or preferential rights, if any, of the holders of shares of such series to subscribe for, purchase, receive, or otherwise acquire any part of any new or additional issue of stock of any class, whether now or hereafter authorized, or of any bonds, debentures, notes, or other securities of the Company, whether or not convertible into shares of stock with the Company. |
All shares of preferred stock offered hereby
will, when issued, be fully paid and nonassessable, including shares of preferred stock issued upon the exercise of preferred stock
warrants or subscription rights, if any.
Although our Board has no intention at the
present time of doing so, it could authorize the issuance of a series of preferred stock that could, depending on the terms of
such series, impede the completion of a merger, tender offer or other takeover attempt.
Anti-Takeover Provisions
Nevada Revised Statutes
Acquisition of Controlling
Interest Statutes . Nevada’s “acquisition of controlling interest” statutes contain provisions governing
the acquisition of a controlling interest in certain Nevada corporations. These “control share” laws provide generally
that any person that acquires a “controlling interest” in certain Nevada corporations may be denied certain voting
rights, unless a majority of the disinterested stockholders of the corporation elects to restore such voting rights. These statutes
provide that a person acquires a “controlling interest” whenever a person acquires shares of a subject corporation
that, but for the application of these provisions of the Nevada Revised Statutes, would enable that person to exercise (1) one-fifth
or more, but less than one-third, (2) one-third or more, but less than a majority or (3) a majority or more, of all of the voting
power of the corporation in the election of directors. Once an acquirer crosses one of these thresholds, shares which it acquired
in the transaction taking it over the threshold and within the 90 days immediately preceding the date when the acquiring person
acquired or offered to acquire a controlling interest become “control shares” to which the voting restrictions described
above apply. Our articles of incorporation and bylaws currently contain no provisions relating to these statutes, and unless our
articles of incorporation or bylaws in effect on the tenth day after the acquisition of a controlling interest were to provide
otherwise, these laws would apply to us if we were to (i) have 200 or more stockholders of record (at least 100 of which have addresses
in the State of Nevada appearing on our stock ledger) and (ii) do business in the State of Nevada directly or through an affiliated
corporation. As of January 15, 2013, we have over 200 record stockholders, but do not have 100 stockholders of records with Nevada
addresses appearing on our stock ledger. If these laws were to apply to us, they might discourage companies or persons interested
in acquiring a significant interest in or control of the Company, regardless of whether such acquisition may be in the interest
of our stockholders.
Combinations with Interested Stockholders
Statutes . Nevada’s “combinations with interested stockholders” statutes prohibit certain business “combinations”
between certain Nevada corporations and any person deemed to be an “interested stockholder” for two years after the
such person first becomes an “interested stockholder” unless (i) the corporation’s board of directors approves
the combination (or the transaction by which such person becomes an “interested stockholder”) in advance, or (ii) the
combination is approved by the board of directors and sixty percent of the corporation’s voting power not beneficially owned
by the interested shareholder, its affiliates and associates. Furthermore, in the absence of prior approval certain restrictions
may apply even after such two-year period. For purposes of these statutes, an “interested stockholder” is any person
who is (x) the beneficial owner, directly or indirectly, of ten percent or more of the voting power of the outstanding voting shares
of the corporation, or (y) an affiliate or associate of the corporation and at any time within the two previous years was the beneficial
owner, directly or indirectly, of ten percent or more of the voting power of the then outstanding shares of the corporation. The
definition of the term “combination” is sufficiently broad to cover most significant transactions between the corporation
and an “interested stockholder”. Subject to certain timing requirements set forth in the statutes, a corporation may
elect not to be governed by these statutes. We have not included any such provision in our articles of incorporation.
The effect of these statutes may be to potentially
discourage parties interested in taking control of the Company from doing so if it cannot obtain the approval of our board of directors.
Transfer Agent
and Registrar
The Transfer Agent and Registrar for our
common stock is VStock Transfer, LLC, 18 Lafayette Place, Woodmere, NY 11598.
DESCRIPTION OF WARRANTS
The following description, together with
the additional information we may include in any applicable prospectus supplements, summarizes the material terms and provisions
of the warrants that we may offer under this prospectus and the related warrant agreements and warrant certificates. While the
terms summarized below will apply generally to any warrants that we may offer, we will describe the particular terms of any series
of warrants in more detail in the applicable prospectus supplement. If we indicate in the prospectus supplement, the terms of any
warrants offered under that prospectus supplement may differ from the terms described below. If there are differences between that
prospectus supplement and this prospectus, the prospectus supplement will control. Thus, the statements we make in this section
may not apply to a particular series of warrants. Specific warrant agreements will contain additional important terms and
provisions and will be incorporated by reference as an exhibit to the registration statement which includes this prospectus.
General
We may issue warrants for the purchase of
common stock and/or preferred stock in one or more series. We may issue warrants independently or together with common stock and/or
preferred stock, and the warrants may be attached to or separate from these securities.
We will evidence each series of warrants
by warrant certificates that we may issue under a separate agreement. We may enter into the warrant agreement with a warrant agent.
Each warrant agent may be a bank that we select which has its principal office in the United States and a combined capital and
surplus of at least $100,000,000. We may also choose to act as our own warrant agent. We will indicate the name and address of
any such warrant agent in the applicable prospectus supplement relating to a particular series of warrants.
We will describe in the applicable prospectus
supplement the terms of the series of warrants, including:
|
• |
|
the offering price and aggregate number of warrants offered; |
|
• |
|
the currency for which the warrants may be purchased; |
|
• |
|
if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security; |
|
• |
|
if applicable, the date on and after which the warrants and the related securities will be separately transferable; |
|
• |
|
in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise; |
|
• |
|
the warrant agreement under which the warrants will be issued; |
|
• |
|
the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreement and the warrants; |
|
• |
|
anti-dilution provisions of the warrants, if any; |
|
• |
|
the terms of any rights to redeem or call the warrants; |
|
• |
|
any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants; |
|
• |
|
the dates on which the right to exercise the warrants will commence and expire or, if the warrants are not continuously exercisable during that period, the specific date or dates on which the warrants will be exercisable; |
|
• |
|
the manner in which the warrant agreement and warrants may be modified; |
|
• |
|
the identities of the warrant agent and any calculation or other agent for the warrants; |
|
• |
|
federal income tax consequences of holding or exercising the warrants; |
|
• |
|
the terms of the securities issuable upon exercise of the warrants; |
|
• |
|
any securities exchange or quotation system on which the warrants or any securities deliverable upon exercise of the warrants may be listed; and |
|
• |
|
any other specific terms, preferences, rights or limitations of or restrictions on the warrants. |
Before exercising their warrants, holders
of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including in the case
of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or, payments upon our liquidation,
dissolution or winding up or to exercise voting rights, if any.
Exercise of Warrants
Each warrant will entitle the holder to
purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable
prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise
the warrants at any time up to 5:00 P.M. eastern time on the expiration date that we set forth in the applicable prospectus supplement.
After the close of business on the expiration date, unexercised warrants will become void.
Holders of the warrants may exercise the
warrants by delivering the warrant certificate representing the warrants to be exercised together with specified information, and
paying the required amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement.
We will set forth on the reverse side of the warrant certificate, and in the applicable prospectus supplement, the information
that the holder of the warrant will be required to deliver to the warrant agent.
Until the warrant is properly exercised,
no holder of any warrant will be entitled to any rights of a holder of the securities purchasable upon exercise of the warrant.
Upon receipt of the required payment and
the warrant certificate properly completed and duly executed at the corporate trust office of the warrant agent or any other office
indicated in the applicable prospectus supplement, we will issue and deliver the securities purchasable upon such exercise. If
fewer than all of the warrants represented by the warrant certificate are exercised, then we will issue a new warrant certificate
for the remaining amount of warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender
securities as all or part of the exercise price for warrants.
Enforceability of Rights By Holders of Warrants
Any warrant agent will act solely as our
agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder
of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will
have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty
or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may,
without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right
to exercise, and receive the securities purchasable upon exercise of, its warrants in accordance with their terms.
Warrant Agreement Will Not Be Qualified Under Trust Indenture
Act
No warrant agreement will be qualified as
an indenture, and no warrant agent will be required to qualify as a trustee, under the Trust Indenture Act. Therefore, holders
of warrants issued under a warrant agreement will not have the protection of the Trust Indenture Act with respect to their warrants.
Governing Law
Each warrant agreement and any warrants
issued under the warrant agreements will be governed by Nevada law.
Calculation Agent
Calculations relating to warrants may be
made by a calculation agent, an institution that we appoint as our agent for this purpose. The prospectus supplement for a
particular warrant will name the institution that we have appointed to act as the calculation agent for that warrant as of the
original issue date for that warrant. We may appoint a different institution to serve as calculation agent from time to time after
the original issue date without the consent or notification of the holders.
The calculation agent’s determination
of any amount of money payable or securities deliverable with respect to a warrant will be final and binding in the absence of
manifest error.
DESCRIPTION OF UNITS
We may issue units comprised of one or more
of the other securities described in this prospectus in any combination. Each unit will be issued so that the holder of the unit
is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a
holder of each included security. The unit agreement under which a unit is issued may provide that the securities included in the
unit may not be held or transferred separately, at any time or at any time before a specified date.
The applicable prospectus supplement will
describe:
|
• |
|
the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately; |
|
• |
|
any unit agreement under which the units will be issued; |
|
• |
|
any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units; and |
|
• |
|
whether the units will be issued in fully registered or global form. |
The applicable prospectus supplement will
describe the terms of any units. The preceding description and any description of units in the applicable prospectus supplement
does not purport to be complete and is subject to and is qualified in its entirety by reference to the unit agreement and, if
applicable, collateral arrangements and depositary arrangements relating to such units.
PLAN OF DISTRIBUTION
We or the selling stockholder may sell the
securities being offered pursuant to this prospectus through underwriters or dealers, through agents, or directly to one or more
purchasers or through a combination of these methods. The applicable prospectus supplement will describe the terms of the
offering of the securities, including:
|
• |
|
the name or names of any underwriters, if any, and if required, any dealers or agents; |
|
• |
|
the purchase price of the securities and the proceeds we will receive from the sale; |
|
• |
|
any underwriting discounts and other items constituting underwriters’ compensation; |
|
• |
|
any discounts or concessions allowed or reallowed or paid to dealers; and |
|
• |
|
any securities exchange or market on which the securities may be listed. |
We may distribute the securities from time
to time in one or more transactions at:
|
• |
|
a fixed price or prices, which may be changed; |
|
• |
|
market prices prevailing at the time of sale; |
|
• |
|
prices related to such prevailing market prices; or |
|
• |
|
negotiated prices. |
Only underwriters named in the prospectus
supplement are underwriters of the securities offered by the prospectus supplement.
If underwriters are used in an offering,
we will execute an underwriting agreement with such underwriters and will specify the name of each underwriter and the terms of
the transaction (including any underwriting discounts and other terms constituting compensation of the underwriters and any dealers)
in a prospectus supplement. The securities may be offered to the public either through underwriting syndicates represented by managing
underwriters or directly by one or more investment banking firms or others, as designated. If an underwriting syndicate is used,
the managing underwriter(s) will be specified on the cover of the prospectus supplement. If underwriters are used in the sale,
the offered securities will be acquired by the underwriters for their own accounts and may be resold from time to time in one or
more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the time
of sale. Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may be changed from
time to time. Unless otherwise set forth in the prospectus supplement, the obligations of the underwriters to purchase the offered
securities will be subject to conditions precedent and the underwriters will be obligated to purchase all of the offered securities
if any are purchased.
We may grant to the underwriters options
to purchase additional securities to cover over-allotments, if any, at the public offering price, with additional underwriting
commissions or discounts, as may be set forth in a related prospectus supplement. The terms of any over-allotment option will be
set forth in the prospectus supplement for those securities.
If we use a dealer in the sale of the securities
being offered pursuant to this prospectus or any prospectus supplement, we will sell the securities to the dealer, as principal. The
dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale. The
names of the dealers and the terms of the transaction will be specified in a prospectus supplement.
We may sell the securities directly or through
agents we designate from time to time. We will name any agent involved in the offering and sale of securities and we will
describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise,
any agent will act on a best-efforts basis for the period of its appointment.
We may authorize agents or underwriters
to solicit offers by institutional investors to purchase securities from us at the public offering price set forth in the prospectus
supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will
describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus
supplement.
In connection with the sale of the securities,
underwriters, dealers or agents may receive compensation from us or from purchasers of the common stock for whom they act as agents
in the form of discounts, concessions or commissions. Underwriters may sell the securities to or through dealers, and those dealers
may receive compensation in the form of discounts, concessions or commissions from the underwriters or commissions from the purchasers
for whom they may act as agents. Underwriters, dealers and agents that participate in the distribution of the securities, and any
institutional investors or others that purchase common stock directly and then resell the securities, may be deemed to be underwriters,
and any discounts or commissions received by them from us and any profit on the resale of the common stock by them may be deemed
to be underwriting discounts and commissions under the Securities Act.
We may provide agents and underwriters with
indemnification against particular civil liabilities, including liabilities under the Securities Act, or contribution with respect
to payments that the agents or underwriters may make with respect to such liabilities. Agents and underwriters may engage in transactions
with, or perform services for, us in the ordinary course of business.
In addition, we may enter into derivative
transactions with third parties (including the writing of options), or sell securities not covered by this prospectus to third
parties in privately negotiated transactions. If the applicable prospectus supplement indicates, in connection with such a transaction,
the third parties may, pursuant to this prospectus and the applicable prospectus supplement, sell securities covered by this prospectus
and the applicable prospectus supplement. If so, the third party may use securities borrowed from us or others to settle such sales
and may use securities received from us to close out any related short positions. We may also loan or pledge securities covered
by this prospectus and the applicable prospectus supplement to third parties, who may sell the loaned securities or, in an event
of default in the case of a pledge, sell the pledged securities pursuant to this prospectus and the applicable prospectus supplement.
The third party in such sale transactions will be an underwriter and will be identified in the applicable prospectus supplement
or in a post-effective amendment.
To facilitate an offering of a series of
securities, persons participating in the offering may engage in transactions that stabilize, maintain, or otherwise affect the
market price of the securities. This may include over-allotments or short sales of the securities, which involves the sale by persons
participating in the offering of more securities than have been sold to them by us. In those circumstances, such persons would
cover such over-allotments or short positions by purchasing in the open market or by exercising the over-allotment option granted
to those persons. In addition, those persons may stabilize or maintain the price of the securities by bidding for or purchasing
securities in the open market or by imposing penalty bids, whereby selling concessions allowed to underwriters or dealers participating
in any such offering may be reclaimed if securities sold by them are repurchased in connection with stabilization transactions.
The effect of these transactions may be to stabilize or maintain the market price of the securities at a level above that which
might otherwise prevail in the open market. Such transactions, if commenced, may be discontinued at any time. We make no representation
or prediction as to the direction or magnitude of any effect that the transactions described above, if implemented, may have on
the price of our securities.
Any common stock sold pursuant to a prospectus
supplement will be eligible for quotation and trading on the OTC QB. Any underwriters to whom securities are sold by us for public
offering and sale may make a market in the securities, but such underwriters will not be obligated to do so and may discontinue
any market making at any time without notice.
In order to comply with the securities laws
of some states, if applicable, the securities offered pursuant to this prospectus will be sold in those states only through registered
or licensed brokers or dealers. In addition, in some states securities may not be sold unless they have been registered or qualified
for sale in the applicable state or an exemption from the registration or qualification requirement is available and complied with.
In compliance with guidelines of the Financial
Industry Regulatory Authority, or FINRA, the maximum consideration or discount to be received by any FINRA member or independent
broker dealer may not exceed 8% of the aggregate amount of the securities offered pursuant to this prospectus and any applicable
prospectus supplement.
LEGAL MATTERS
The validity of the issuance of the securities
offered hereby will be passed upon for us by Sichenzia Ross Friedman Ference LLP, New York, New York.
EXPERTS
The consolidated
financial statements of Amarantus BioScience Holdings, Inc. as of and for the years ended December 31, 2014 and 2013
incorporated in this prospectus by reference to the Annual Report on Form 10-K of Amarantus BioScience Holdings, Inc. for the
year ended December 31, 2014 have been so incorporated in reliance on the report (which contains an explanatory paragraph
related to the Company’s ability to continue as a going concern) of Marcum LLP, Independent Registered
Public Accounting Firm, given on the authority of said firm as experts in accounting and auditing.
WHERE YOU CAN FIND MORE INFORMATION
This prospectus constitutes a part of a
registration statement on Form S-3 filed under the Securities Act. As permitted by the SEC’s rules, this prospectus
and any prospectus supplement, which form a part of the registration statement, do not contain all the information that is included
in the registration statement. You will find additional information about us in the registration statement. Any statements
made in this prospectus or any prospectus supplement concerning legal documents are not necessarily complete and you should read
the documents that are filed as exhibits to the registration statement or otherwise filed with the SEC for a more complete understanding
of the document or matter.
We file annual, quarterly and current reports,
proxy statements and other information with the SEC. You may read, without charge, and copy the documents we file at the
SEC’s public reference rooms in Washington, D.C. at 100 F Street, NE, Room 1580, Washington, DC 20549, or in New York, New
York and Chicago, Illinois. You can request copies of these documents by writing to the SEC and paying a fee for the copying
cost. Please call the SEC at 1-800-SEC-0330 for further information on the public reference rooms. Our SEC filings are
also available to the public at no cost from the SEC’s website at http://www.sec.gov.
INCORPORATION OF DOCUMENTS BY REFERENCE
We have filed a registration statement on
Form S-3 with the Securities and Exchange Commission under the Securities Act. This prospectus is part of the registration statement
but the registration statement includes and incorporates by reference additional information and exhibits. The Securities and Exchange
Commission permits us to “incorporate by reference” the information contained in documents we file with the Securities
and Exchange Commission, which means that we can disclose important information to you by referring you to those documents rather
than by including them in this prospectus. Information that is incorporated by reference is considered to be part of this prospectus
and you should read it with the same care that you read this prospectus. Information that we file later with the Securities and
Exchange Commission will automatically update and supersede the information that is either contained, or incorporated by reference,
in this prospectus, and will be considered to be a part of this prospectus from the date those documents are filed. We have filed
with the Securities and Exchange Commission, and incorporate by reference in this prospectus:
|
• |
|
Annual Report on Form 10-K for the year ended December 31,
2014 filed with the SEC on April 6, 2015; |
|
|
|
|
|
• |
|
Quarterly Reports on Form 8-K or 8-K/A filed with the SEC on
January 12, 2015, January 13, 2015, January 14, 2015, January 15, 2015, February 13, 2015, February 25, 2015, February 26, 2015,
March 3, 2015, March 25, 2015, March 31, 2015, April 2, 2015, April 28, 2015 and April 29, 2015; and |
|
|
|
|
|
• |
|
The description of our common stock contained in our Form 8-A filed with the SEC on August 2, 2013. |
We
also incorporate by reference all additional documents that we file with the Securities and Exchange Commission under the terms
of Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act that are made after the initial filing date of the registration statement
of which this prospectus is a part until the offering of the particular securities covered by a prospectus supplement or term sheet
has been completed. All filings from the date of the initial registration statement and prior to effectiveness of the registration
statement shall be deemed to be incorporated by reference into the prospectus. We
are not, however, incorporating, in each case, any documents or information that we are deemed to furnish and not file in accordance
with Securities and Exchange Commission rules.
You may request, and we will provide you
with, a copy of these filings, at no cost, by calling us at (415) 688-4484 or by writing to us at the following address:
Amarantus BioScience Holdings, Inc.
655 Montgomery Street, Suite 900
San Francisco, CA 94111
Attn.: Corporate Secretary
PART II INFORMATION NOT REQUIRED IN PROSPECTUS
Item 14. Other Expenses of Issuance and Distribution.
The following table sets forth an estimate
of the fees and expenses relating to the issuance and distribution of the securities being registered hereby, other than underwriting
discounts and commissions, all of which shall be borne by the Registrant. All of such fees and expenses, except for the SEC
Registration Fee and the FINRA filing fee, are estimated:
SEC registration fee | |
$ | 17,430 | |
FINRA filing fee | |
$ | 24,000 | |
Transfer agent’s fees and expenses | |
$ | 2,000 | |
Legal fees and expenses | |
$ | 30,000 | |
Printing fees and expenses | |
$ | 7,000 | |
Accounting fees and expenses | |
$ | 10,000 | |
Miscellaneous fees and expenses | |
$ | 4,570 | |
| |
| | |
Total | |
$ | 95,000 | |
Item 15. Indemnification of Officers and Directors.
Section 78.7502(1) of the Nevada Revised Statutes provides that
a corporation may indemnify any person who was or is a party, or is threatened to be made a party, to any threatened, pending or
completed action, suit or proceeding, whether civil, criminal, administrative or investigative (except in an action brought by
or on behalf of the corporation) if that person is or was a director, officer, employee or agent of the corporation, or is or was
serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise, against
expenses, including attorneys' fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by that person
in connection with such action, suit or proceeding, if that person acted in good faith and in a manner which that person reasonably
believed to be in, or not opposed to, the best interests of the corporation, and, with respect to any criminal action or proceedings,
had no reasonable cause to believe his conduct was unlawful. The termination of any action, suit or proceeding by judgment, order,
settlement, conviction or upon a plea of nolo contendere or its equivalent, alone, does not create a presumption that the person
did not act in good faith and in a manner which the person reasonably believed to be in, or not opposed to, the best interests
of the corporation, and that, with respect to any criminal action or proceeding, the person had reasonable cause to believe his
action was unlawful.
Section 78.7502(2) of the Nevada Revised Statutes provides that
a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or
completed action or suit brought by or on behalf of the corporation to procure a judgment in its favor because the person acted
in any of the capacities set forth above, against expenses, including amounts paid in settlement and attorneys' fees, actually
and reasonably incurred by that person in connection with the defense or settlement of such action or suit, if the person acted
in accordance with the standard set forth above, except that no indemnification may be made in respect of any claim, issue or matter
as to which such person shall have been adjudged by a court of competent jurisdiction after exhaustion of all appeals therefrom
to be liable to the corporation or for amounts paid in settlement to the corporation unless and only to the extent that the court
in which such action or suit was brought or other court of competent jurisdiction determines that, in view of all the circumstances
of the case, such person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper.
Section 78.7502(3) of the Nevada Revised Statutes further provides
that, to the extent a director or officer of a corporation has been successful on the merits or otherwise in the defense of any
action, suit or proceeding referred to in subsections 1 and 2 thereof, or in the defense of any claim, issue or matter therein,
that person shall be indemnified by the corporation against expenses (including attorneys' fees) actually and reasonably incurred
by that person in connection therewith.
Section 78.751 of the Nevada Revised Statutes provides that
unless indemnification is ordered by a court, the determination to provide indemnification must be made by the stockholders, by
a majority vote of a quorum of the board of directors who were not parties to the action, suit or proceeding, or in specified circumstances
by independent legal counsel in a written opinion. In addition, the articles of incorporation, bylaws or an agreement made by the
corporation may provide for the payment of the expenses of a director or officer of the expenses of defending an action as incurred
upon receipt of an undertaking to repay the amount if it is ultimately determined by a court of competent jurisdiction that the
person is not entitled to indemnification. Section 78.751 of the Nevada Revised Statutes further provides that the indemnification
provided for therein shall not be deemed exclusive of any other rights to which the indemnified party may be entitled and that
the scope of indemnification shall continue as to directors, officers, employees or agents who have ceased to hold such positions,
and to their heirs, executors and administrators.
Section 78.752 of the Nevada Revised Statutes provides that
a corporation may purchase and maintain insurance on behalf of a director, officer, employee or agent of the corporation against
any liability asserted against him or incurred by him in any such capacity or arising out of his status as such whether or not
the corporation would have the authority to indemnify him against such liabilities and expenses.
Item 16. Exhibits.
Exhibit No. |
Description |
|
|
1.1* |
Form of Underwriting Agreement |
|
|
3.1 |
Articles of Incorporation of Amarantus BioScience, Inc. filed with the Secretary of State of Nevada on March 22, 2013 (Incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed April 1, 2013). |
|
|
3.2 |
Certificate of Amendment to Certificate of Incorporation (Incorporated by reference to Current Report on Form 8-K filed October 14, 2011). |
|
|
3.3 |
Certificate of Amendment to the Certificate of Incorporation (Incorporated by reference to Current Report on Form 8-K filed November 14, 2012). |
|
|
3.4 |
Current Report on Form 8-K filed November 27, 2012. |
|
|
3.5 |
Bylaws (Incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed April 1, 2013). |
|
|
4.1 |
Specimen Certificate for Common Stock |
|
|
4.2* |
Form of Warrant Agreement (including Warrant Certificate) |
|
|
4.3* |
Specimen Preferred Stock Certificate and Form of Certificate of Designation of Preferred Stock |
|
|
4.4* |
Form of Unit Agreement (including Unit Certificate) |
|
|
5.1 |
Opinion of Sichenzia Ross Friedman Ference LLP |
|
|
23.1 |
Consent of Sichenzia Ross Friedman Ference LLP (included in Exhibit 5.1). |
|
|
23.2 |
Consent of Marcum LLP. |
|
|
24.1 |
Power of Attorney (included on signature pages to the registration statement) |
|
*
|
To the extent applicable, to be filed by an amendment or as an exhibit to a document filed under the Securities Exchange Act of 1934, as amended, and incorporated by reference herein. |
Item 17. Undertakings.
|
(a) |
The undersigned registrant hereby undertakes: |
(1) To file, during any period in which
offers or sales are being made, a post-effective amendment to this registration statement:
(i) To include any prospectus required
by Section 10(a)(3) of the Securities Act;
(ii) To reflect in the prospectus
any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment
thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration
statement. Notwithstanding the foregoing, any increase or decrease in the volume of securities offered (if the total dollar value
of the securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated
maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the
aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth
in the “Calculation of Registration Fee” table in the effective registration statement; and
(iii) To include any material information
with respect to the plan of distribution not previously disclosed in this registration statement or any material change to such
information in this registration statement;
provided, however, that the undertakings
set forth in paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) above do not apply if the information required to be included in
a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant
pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)
that are incorporated by reference in this registration statement or is contained in a form of prospectus filed pursuant to Rule
424(b) that is part of this registration statement;
(2) That, for the purpose of determining
any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating
to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide
offering thereof.
(3) To remove from registration by means
of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
(4) That, for the purpose of determining
liability under the Securities Act to any purchaser:
If the registrant is relying on Rule 430B;
(i) Each prospectus filed by the
registrant pursuant to Rule 424 (b)(3) shall be deemed to be part of this registration statement as of the date the filed prospectus
was deemed part of and included in the registration statement; and
(ii) Each prospectus required to
be filed pursuant to Rule 424 (b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to
an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x) for the purpose of providing the information required by
Section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier
of the date of the Securities Act prospectus is first used after effectiveness or the date of the first contract of sale of securities
in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that
is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to
the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement
or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference
into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of
contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or
prospectus that was part of the registration statement or made in any such document immediately prior to such effective date; or
(iii) If the registrant is subject
to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other
than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to
be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that
no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated
or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will,
as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the
registration statement or prospectus that was part of the registration statement or made in any such document immediately prior
to such date of first use.
(5) That, for the purpose of determining
liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities:
The undersigned registrant undertakes that
in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting
method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of
the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell
such securities to such purchaser:
(i) Any preliminary prospectus or
prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;
(ii) Any free writing prospectus
relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;
(iii) The portion of any other free
writing prospectus relating to the offering containing material information about the undersigned registrant or its securities
provided by or on behalf of the undersigned registrant; and
(iv) Any other communication
that is an offer in the offering made by the undersigned registrant to the purchaser.
|
(b) |
The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
|
(h) |
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. |
SIGNATURES
Pursuant to the requirements of the Securities
Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form S-3 and has duly caused this Form S-3 to be signed on its behalf by the undersigned, thereunto duly authorized,
in San Francisco, California, on the 4th day of May 2015.
|
AMARANTUS BIOSCIENCE HOLDINGS, INC. |
|
|
|
|
By: |
/s/ Gerald Commissiong |
|
|
Gerald Commissiong |
|
|
Chief Executive Officer |
|
|
(Principal Executive Officer) |
|
|
|
|
By: |
/s/ Robert Farrell |
|
|
Robert Farrell |
|
|
Chief Financial Officer |
|
|
(Principal Financial and Accounting Officer) |
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that each
person whose signature appears below constitutes and appoints Gerald Commissiong, his true and lawful attorney-in-fact and agent
with full power of substitution and re-substitution, for him/her and in his name, place and stead, in any and all capacities to
sign any or all amendments (including, without limitation, post-effective amendments) to this Registration Statement, any related
Registration Statement filed pursuant to Rule 462(b) under the Securities Act of 1933 and any or all pre- or post-effective amendments
thereto, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities
and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every
act and thing requisite and necessary to be done in and about the premises, as fully for all intents and purposes as he or she
might or could do in person, hereby ratifying and confirming that said attorney-in-fact and agent, or any substitute or substitutes
for him, may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act of 1933, the
following persons in the capacities and on the dates indicated have signed this Registration Statement below.
Signature |
|
Title |
Date |
|
|
|
|
/s/ Gerald Commissiong |
|
Chief Executive Officer, President and Director |
May 4, 2015 |
Gerald Commissiong |
|
(Principal Executive Officer) |
|
|
|
|
|
/s/ Robert Farrell |
|
Chief Financial Officer |
May 4, 2015 |
Robert Farrell |
|
(Principal Financial and Accounting Officer) |
|
|
|
|
|
/s/ Marc E. Faerber |
|
Controller, Treasurer, Vice President of Financial Operations, |
May 4, 2015 |
Marc E. Faerber |
|
and Secretary |
|
|
|
|
|
/s/ John W. Commissiong |
|
Director |
May 4, 2015 |
John W. Commissiong |
|
|
|
|
|
|
|
/s/ Robert L. Harris |
|
Director |
May 4, 2015 |
Robert L. Harris |
|
|
|
|
|
|
|
/s/ David Lowe |
|
Director |
May 4, 2015 |
David Lowe |
|
|
|
|
|
|
|
/s/ David Huffman |
|
Director |
May 4, 2015 |
Donald Huffman |
|
|
|
|
|
|
|
/s/ Iain Ross |
|
Director |
May 4, 2015 |
Iain Ross |
|
|
|
|
|
|
|
/s/ Joseph Rubinfeld |
|
Director |
May 4, 2015 |
Joseph Rubinfeld |
|
|
|
Exhibit 4.1
EXHIBIT 5.1
SICHENZIA ROSS FRIEDMAN FERENCE LLP
61 Broadway, 32nd Floor
New York, NY 10006
Telephone: (212) 930-9700
Facsimile: (212) 930-9725
May 4, 2015
Amarantus Bioscience Holdings, Inc.
655 Montgomery Street, Suite 900
San Francisco, California 94111
Re: Amarantus Bioscience Holdings, Inc.’s
Registration Statement on Form S-3
Ladies and Gentlemen:
We have acted as special
counsel to Amarantus Bioscience Holdings, Inc., a Nevada corporation (the “Company”), in connection with the
preparation and filing of the Registration Statement on Form S-3 (the “Registration Statement”), filed by the
Company with the Securities and Exchange Commission (the “Commission”) pursuant to the Securities Act of 1933, as amended
(the “Securities Act”) relating to an aggregate initial offering price not to exceed $150,000,000 of one or more of
the following securities which may be issued by the Company, from time to time, under the Registration Statement: (i) shares
of the Company’s common stock, $0.001 par value per share (the “Common Stock”), which may include shares of Common
Stock issuable upon the conversion or exercise of the other Securities included in the Registration Statement, (ii) shares
of the Company’s preferred stock, $0.001 par value per share (the “Preferred Stock”), which may include shares
of Preferred Stock issuable upon the exercise of the Warrants (as defined herein) included in the Registration Statement, (iii) warrants
(the “Warrants”) to purchase Common Stock or Preferred Stock, which may be issued pursuant to a warrant agreement (the
“Warrant Agreement”) between the Company and a designated warrant agent (the “Warrant Agent”) and (iv)
units (the “Units”) comprised of any combination of the foregoing Securities, which may be issued pursuant to a unit
agreement (the “Unit Agreement”) between the Company and a designated unit agent (the “Unit Agent”). The
Common Stock, Preferred Stock, Warrants and Units are collectively referred to herein as the "Securities" and each, a
"Security."
This opinion is being delivered
in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Act and no opinion is expressed herein pertaining
to the Registration Statement, any prospectus contained therein or any prospectus supplement hereafter filed, other than with respect
to the enforceability of the Applicable Agreements (defined below) and the legally-issued nature of the Securities.
We have reviewed such records,
documents, agreements and certificates, and examined such questions of law, as we have considered necessary or appropriate to express
the opinions set forth below. In making our examination of records, documents, agreements and certificates, we have assumed the
authenticity of the same, the correctness of the information contained therein, the genuineness of all signatures, the authority
of all persons entering and maintaining records or executing documents, agreements and certificates, and the conformity to authentic
originals of all items submitted to us as copies (whether certified, conformed, photostatic or by other electronic means) of records,
documents, agreements or certificates. In rendering our opinions, we have relied as to factual matters upon certificates of public
officials and certificates and representations of officers of the Company.
Based upon and subject
to the foregoing and to the other assumptions, qualifications, limitations and exceptions set forth herein, we are of the opinion
that:
1. With respect to any
offering of Common Stock by the Company pursuant to the Registration Statement (the “Offered Common Stock”), the shares
of Offered Common Stock (including any Offered Common Stock duly issued upon conversion or exchange of other securities) will be
duly authorized, validly issued, fully paid and non-assessable.
2. With respect to any
offering of Preferred Stock by the Company pursuant to the Registration Statement (the “Offered Preferred Stock”),
when a certificate of designation with respect to the Offered Preferred Stock has been filed with and accepted for filing by the
Delaware Secretary of State, the shares of Offered Preferred Stock, (including any Offered Preferred Stock duly issued upon conversion
or exchange of other securities) will be duly authorized, validly issued, fully paid and non-assessable.
3. With respect
to any offering of Warrants by the Company pursuant to the Registration Statement (the “Offered Warrants”), when the
Warrant Agreement, in the form to be filed as an exhibit to a post-effective amendment to the Registration Statement or incorporated
by reference therein, relating to such Warrants has been duly authorized, executed and delivered by each of the Warrant Agent and
the Company, the Offered Warrants will constitute valid and binding obligations of the Company, enforceable against the Company
in accordance with their terms.
4. With respect to
any offering of Units by the Company pursuant to the Registration Statement (the “Offered Units”), when (a) the
Unit Agreement, in the form to be filed as an exhibit to a post-effective amendment to the Registration Statement or incorporated
by reference therein, relating to such Units has been duly authorized, executed and delivered by each of the Unit Agent and the
Company and (b) when the Warrant Agreement, in the form to be filed as an exhibit to a post-effective amendment to the Registration
Statement, which is a components of such Offered Units, has been duly authorized, executed and delivered by each of the Warrant
Agent and the Company, such Units will be validly issued and will entitle the holder thereof to the rights specified in the Unit
Agreement, if any.
The opinions set forth
herein are subject to the following assumptions, qualifications, limitations and exceptions being true and correct at or before
the time of the delivery of any Securities offered pursuant to the Registration Statement (the “Offered Securities”):
(i) the Board of
Directors, including any appropriate committee appointed thereby, and appropriate officers of the Company shall have duly established
the terms of the Offered Securities;
(ii) the Board of
Directors, including any appropriate committee appointed thereby, and appropriate officers of the Company shall have duly authorized,
and taken any other necessary corporate action to approve the creation, issuance and sale of, the Offered Securities and related
matters (including without limitation with respect to
Offered Preferred Shares, the creation, execution,
acknowledgment and filing of a certificate of designation stating the number, designation, relative rights, preferences and limitations
of any such Offered Preferred Shares in accordance with the applicable provisions of the corporate laws of the State of Delaware)
and such authorizations and actions have not been rescinded;
(iii) the terms of
the issuance and sale of the Offered Securities have been duly established in conformity with the restated certificate of incorporation,
the by-laws, and other similar formation documents of the Company (the “Formation Documents”) and any other relevant
agreement, including, but not limited to, the Warrant Agreement and the Unit Agreement (collectively, the “Applicable Agreements”),
so as not to violate any applicable law, the Formation Documents (subject to the further assumption that such Formation Documents
have not been amended from the date hereof in a manner that would affect the validity of any of the opinions rendered herein),
or result in a default under or breach of any agreement or instrument binding upon the Company and so as to comply with any restriction
imposed by any court or governmental body having jurisdiction over the Company;
(iv) the Offered
Securities have been duly authenticated, authorized, executed, countersigned, registered and delivered upon payment of the agreed-upon
legal consideration therefor (in an amount per share of Offered Common Stock or Offered Preferred Stock, as appropriate, not less
than the par value thereof) and have been duly issued and sold in accordance with any relevant agreement (including, but not limited
to, any Applicable Agreements), any underwriting agreement with respect to the Offered Securities or any other duly authorized,
executed and delivered, applicable, valid and binding purchase agreement, or as otherwise contemplated by the Registration Statement
or any post-effective amendment thereto, and any prospectus supplement(s) relating thereto;
(vi) the Registration
Statement, as finally amended (including all necessary post-effective amendments) and any additional registration statement filed
under the Securities Act will have been declared effective under the Securities Act and such effectiveness shall not have been
terminated or rescinded;
(vii) appropriate
prospectus supplement(s) shall have been prepared, delivered and filed in compliance with the Securities Act and the applicable
rules and regulations thereunder describing the Offered Securities offered thereby;
(viii) the Offered
Securities shall be issued and sold in compliance with all federal and state securities laws and solely in the manner stated in
the Registration Statement and the applicable prospectus supplement and there shall not have occurred any change in law affecting
the validity of the opinions rendered herein;
(ix) if the Offered
Securities will be sold pursuant to a firm commitment underwritten offering, the underwriting agreement with respect to the Offered
Securities in the form filed as an exhibit to the Registration Statement or any post-effective amendment thereto, or incorporated
by reference therein, has been duly authorized, executed and delivered by the Company and the other parties thereto;
(x) in the case of
an Applicable Agreement or other agreement or instrument pursuant to which any Offered Securities are to be issued, there shall
be no terms or provisions contained therein which would affect the validity of any of the opinions rendered herein and
(xi) in the case of an
Applicable Agreement or other agreement or instrument pursuant to which any Offered Securities are to be issued, we have assumed
that the laws of the State of New York will be chosen to govern such agreement or instrument and that such choice is a valid and
legal provision.
The foregoing opinions
are based upon and expressly limited to the laws of the State of New York and the corporate law of the State of Nevada. We do not
purport to be experts on, or to express any opinion with respect to the applicability thereto, or to the effect, of the laws of
any other jurisdiction or as to matters of local law or the laws of local governmental departments or agencies within the State
of Nevada.
Any opinion set forth herein
as to enforceability of obligations of the Company is subject to: (i) bankruptcy, insolvency, reorganization, fraudulent conveyance,
moratorium or similar laws affecting the enforcement of creditors’ rights generally, and by general principles of equity
(regardless of whether enforcement is sought in a proceeding in equity or at law); (ii) provisions of law which may require
that a judgment for money damages rendered by a court in the United States be expressed only in United States dollars; and (iii) governmental
authority to limit, delay or prohibit the making of payments outside the United States or in foreign currency or composite currency.
Rights to indemnification and contribution may also be limited by federal and state securities laws.
We express no opinion as
to the validity, legally binding effect or enforceability of any provision in any agreement or instrument that (i) requires
or relates to payment of any interest at a rate or in an amount which a court would determine in the circumstances under applicable
law to be commercially unreasonable or a penalty or forfeiture or (ii) relates to governing law and submission by the parties
to the jurisdiction of one or more particular courts.
We hereby consent to the
filing of this opinion as Exhibit 5.1 to the Registration Statement, the Related Registration Statement and to the reference
to this firm under the caption “Legal Matters.” In giving such consent, we do not thereby admit that we are in the
category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended or under the rules and
regulations promulgated by the Securities and Exchange Commission. This opinion is expressed as of the date hereof, and we disclaim
any undertaking to advise you of any subsequent changes in the facts stated or assumed herein or of any subsequent changes in applicable
laws, even where the Offered Securities may be issued from time to time on a delayed or continuous basis.
|
Very truly yours, |
|
|
|
/s/ Sichenzia Ross Friedman Ference LLP |
Exhibit 23.2
Independent
Registered Public Accounting Firm’s Consent
We consent to the incorporation by reference
in this Registration Statement of Amarantus Bioscience Holdings, Inc. on Form S-3 of our report, which includes an explanatory
paragraph as to the Company’s ability to continue as a going concern, dated April 3, 2015 with respect to our audits of
the consolidated financial statements of Amarantus Bioscience Holdings, Inc. as of December 31, 2014 and December 31, 2013 and
for the years ended December 31, 2014 and December 31, 2013 appearing in the Annual Report on Form 10-K of Amarantus Bioscience
Holdings, Inc. for the year ended December 31, 2014. We also consent to the reference to our firm under the heading “Experts”
in the Prospectus, which is part of this Registration Statement.
/s/ Marcum llp
New York, NY
May 4, 2015
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Apr 2023 to Apr 2024